IVAX Receives FDA Approvals for Two Brand Equivalent Products

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements, including the statements regarding IVAX' pending ANDAs and tentative approvals and filing schedule for ANDA submissions, involve risks and uncertainties which may affect the company's business and prospects, including the risks that the launch of lisinopril tablets in 2.5 mg, 5 mg, 10 mg, 20 mg 30 mg and 40 mg strengths or lisinopril/HCTZ tablets in 10 mg, 20/12.5 mg and 20/25 mg strengths will be delayed; that the compounds and products in the IVAX' research pipeline will not be successfully developed, will not receive regulatory approval or will not be successfully commercialized; changing market conditions; the availability and cost of raw materials and other third party products; the impact of competitive products and pricing; that IVAX may not receive approval of its pending ANDAs or final approval of its tentatively approved ANDAs, or that if approved, the products will not be successfully commercialized; that IVAX may not file any additional ANDAs; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's 2001 Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Zestril(R) and Zestoretic(R) tablets are registered trademarks of AstraZeneca. Prinivil(R) and Prinzide(R) tablets are registered trademarks of Merck & Company.